L & S Advisors’s Viking Therapeutics VKTX Stock Holding History

L & S Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-114,988	Closed	-$669K	–	366
2020 Q3	$669K	Sell	114,988 -91,323	-44%	-$629K	0.09%	206
2020 Q2	$1.49M	Buy	206,311 +98,380	+91%	+$653K	0.22%	116
2020 Q1	$505K	Sell	107,931 -71,578	-40%	-$440K	0.1%	174
2019 Q4	$1.44M	Sell	179,509 -34,495	-16%	-$251K	0.18%	119
2019 Q3	$1.47M	Buy	214,004 +15,275	+8%	+$113K	0.21%	136
2019 Q2	$1.65M	Buy	198,729 +27,959	+16%	+$239K	0.22%	117
2019 Q1	$1.7M	Buy	170,770 +53,805	+46%	+$450K	0.23%	97
2018 Q4	$895K	Buy	116,965 +20,400	+21%	+$244K	0.17%	120
2018 Q3	$1.68M	Buy	96,565 +23,530	+32%	+$280K	0.22%	104
2018 Q2	$693K	Buy	+73,035	New	+$486K	0.12%	170

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

L & S Advisors's VKTX Position: Q4 2020 in Review

L & S Advisors sold out of Viking Therapeutics (VKTX) in Q4 2020, closing a stake of 114,988 shares — an estimated $669K sold.

L & S Advisors first reported a position in VKTX in Q2 2018 and held it in 10 quarters. The position peaked at $1.7M in Q1 2019. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2020.

L & S Advisors reported no remaining Viking Therapeutics position as of Q4 2020 after selling out during the quarter.
L & S Advisors sold 114,988 Viking Therapeutics shares in Q4 2020, an estimated $669K.
L & S Advisors first reported a position in Viking Therapeutics in Q2 2018 and held it in 10 quarters.
L & S Advisors's Viking Therapeutics position peaked at $1.7M in Q1 2019.
143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2020.

Based on L & S Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.